Navigation Links
FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
Date:1/31/2012

lydeco was approved ahead of the drug's April 18, 2012, prescription user fee goal date and is designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the United States.

In patients with the G551D mutation, Kalydeco, a pill taken two times a day with fat-containing food, helps the protein made by the CFTR gene function better and as a result, improves lung function and other aspects of CF such as increasing weight gain.

"Kalydeco is the first available treatment that targets the defective CFTR protein, which is the underlying cause of cystic fibrosis," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "This is a breakthrough therapy for the cystic fibrosis community because current therapies only treat the symptoms of this genetic disease."

Two 48-week, placebo-controlled clinical studies involving 213 patients, one in patients ages 12 years and older and another in patients ages 6 years to 11 years, were used to evaluate the safety and efficacy of Kalydeco in CF patients with the G551D mutation. In both studies, treatment with Kalydeco resulted in significant and sustained improvement in lung function.

Kalydeco is effective only in patients with CF who have the G551D mutation. It is not effective in CF patients with two copies of the F508 mutation in the CFTR gene, which is the most common mutation that results in CF. If a patient's mutation status is not known, an FDA-cleared CF mutation test should be used to determine whether the G551D mutation is present.

The most common side effects of Kalydeco include upper respiratory tract infection, headache, stomach ache, rash, diarrhea, and dizziness.

Kalydeco is manufactured by Vertex Pharmaceuticals Inc. of Cambridge, Mass.

For more information:

FDA Voice Blog: How science and collaboration led to a new, "personalized" cystic fibrosis treatment for some patients

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... its pipeline and new product development efforts. In the ... a Phase 2a study of AZ-002 (Staccato ® ... management of patients with acute repetitive seizures.  Additionally, ... product candidates for development - AZ-008 and AZ-009 ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) ... held on Friday, June 17, 2011. At the meeting, shareholders ... of incorporation to increase the total number of authorized shares ... About Cell Therapeutics, Inc. Headquartered in ...
... Pharmaceuticals, Inc. is initiating a voluntary recall of ... by Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and ... Patriot Pharmaceuticals, LLC, a wholly owned subsidiary of ... consumer reports of an uncharacteristic odor thought to ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 2Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 3Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 4Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 5Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 6Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 7
(Date:7/31/2014)... Ce-Classes.com has announced that they are now ... a Systematic Review of Sexual Satisfaction . ... International Journal of Clinical and Health Psychology. , This ... need to have accurate information about sexual satisfaction so ... The material provides a systematic review of 197 ...
(Date:7/31/2014)... In many states and counties across the country, ... life saving drugs. This requirement is for the safety of ... number of ambulances without proper security procedures. , In extreme ... even replaces the vital pain killers with saline. Later, the ... case in Baraboo, Wisconsin last November. According to court documents, ...
(Date:7/31/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:7/31/2014)... Tampa, FL (PRWEB) July 31, 2014 ... 45 hospitals in the U.S. including Florida Hospital ... Term Acute Care, Florida Hospital North Pinellas, Florida ... Heartland Medical Center Sebring, Florida Hospital Heartland Medical ... Hospitals & Health Networks list of Most Wired ...
(Date:7/31/2014)... The vineyards are lush, and the grapes ... to celebrate, folks are gearing up for the annual ... 7, 2014 along the Leelanau Peninsula Wine Trail . ... run through the vineyards start-ing at 9:00 a.m. on Saturday ... course between rows of grapevines offers an experience like no ...
Breaking Medicine News(10 mins):Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2
... help decrease wait time, increase physician productivity,and ... reduce overcrowding,decrease patient wait time, and improve ... endorsed 10 national voluntary consensus standards for,hospital-based ... improve,efficiency and care coordination in emergency departments ...
... out for,the soccer team or training for a dance ... greater than adults. After all, they need,nutrition for growth ... from the foods they consume., Nutritious snacks that ... to,helping young athletes perform at their best. Portable snacks ...
... often must make 2009 plan choices in November, SOUTH ... candidates to choose from at this time of year. For ... usually the,time of the year when they have to choose ... effect in 2009., Many Maine companies offer between two ...
... DALLAS, Oct. 30 Claimsnet.com inc. (OTC,Bulletin Board: CLAI), ... healthcare industry, today reported its,results for the third quarter ... are pleased to report a 27% increase in our ... Claimsnet.,"The increase in overall costs during the third quarter ...
... One errant cough or unexpected,sneeze and the workplace ... As the flu season approaches, HR managers prepare to,deal ... estimates that the cost of influenza to the U.S. ... can range from $71 billion,to $167 billion a year., ...
... VANCOUVER, Oct. 30 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: ... RAMP(R),technology in the 3M(TM) Rapid Detection Flu A+B ... in Washington D.C., officially launching,the RAMP(R) Influenza A/B ... branded,by 3M as the 3M(TM) Rapid Detection Flu ...
Cached Medicine News:Health News:NQF Endorses Measures to Address Care Coordination and Efficiency in Hospital Emergency Departments 2Health News:NQF Endorses Measures to Address Care Coordination and Efficiency in Hospital Emergency Departments 3Health News:Fueling Kids for Sports 2Health News:Health Insurance Open Enrollment Tips 2Health News:Health Insurance Open Enrollment Tips 3Health News:Claimsnet.com Reports Third Quarter 2008 Results 2Health News:Claimsnet.com Reports Third Quarter 2008 Results 3Health News:Going 'Green' May Mean Fewer Colds This Season 2Health News:Going 'Green' May Mean Fewer Colds This Season 3Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 2Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 3Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 4
Liberty Single Piece PMMA Lens with UV Absorber....
... sterile nonpyrogenic, transparent viscoelastic solution of highly ... mg/ml of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25 C and ...
... with optimum molecular weight and viscosity, so ... coats and protects the delicate structures of ... balance of cohesion, adhesion, and pseudoplasticity to ... phaco surgeon expects from an ophthalmic viscoelastic ...
... (1.8%) viscoelastic solution combines maximum intraocular protection ... a deep anterior chamber and protects the ... for routine cataract surgery but can be ... viscoelastic. Combine all these properties with the ...
Medicine Products: